CTLA4 and neoplasm: Over the past decade, ICIs targeting PD-1/PD-L1, CTLA-4, and other molecules that regulate the immune response against cancer have transformed the treatment of a wide variety of cancer types, enhancing survival, and in some cases even leading to complete tumor regressions.